S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CRMD · CorMedix Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$7.79
+0.23
(+3.04%)
● At close: October 21 at 4:00:00 PM EDT
$7.78
-0.01
(-0.13%)
Overnight:
8:06:18 PM EDT
DAY'S RANGE
$7.79
$7.53
$7.84
52-WEEK RANGE
$7.79
$6.13
$13.02
What's happening
- CRMD is up 3.04% today, trading at $7.79. — Live quote
- Volume today (105,050) is well below its 3-month average of 1,181,060. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.29 actual vs. $0.24 estimated (+19.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CRMD
-34.91%
vs S&P 500
-47.69%
1-YEAR RETURN
CRMD
-37.75%
vs S&P 500
-52.31%
6-MONTH RETURN
CRMD
+6.17%
3-MONTH RETURN
CRMD
-7.57%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.29
Est. $0.24
BEAT +19.4%
2026-04-26 (Q1 2026)
$0.49
Est. $0.37
BEAT +31.7%
2026-01-26 (Q4 2025)
$0.16
Est. $0.83
MISS -80.8%
2025-10-26 (Q3 2025)
$1.26
Est. $0.66
BEAT +91.5%
Valuation Measures & Ratios
Enterprise Value4$478.5M
Forward P/E542.63
PEG Ratio60.02
Price / Sales (TTM1)1.28
Price / Book71.34
EV4 / Revenue1.04
EV4 / EBITDA2.01
Profit Margin40.49%
Operating Margin46.95%
Return on Equity (ROE8)44.64%
Return on Assets (ROA9)22.71%
Avg Volume (3M)1,181,060
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $703.5M | $610.0M | $667.7M | $29.0M | $14.1M |
| P/E | 3.65 | 3.25 | 4.57 | 1.23 | -1.31 |
| Price/Book | 1.53 | 1.40 | 1.78 | 0.13 | 0.12 |
| ROE | 41.88% | 42.93% | 39.09% | 10.67% | -9.36% |
| ROA | 21.35% | 23.00% | 19.48% | 9.32% | -7.19% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short15,422,728
Change from Prior Settlement-4.81%
% of Float—
Days to Cover (Short Ratio)18.90
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 156.5% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 40.5%. Finnhub fundamentals ↗
Potential concerns
- Trailing 52-week price return is -37.7%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-10-19; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CRMD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $101.9M | $127.4M | — | $39.7M | $39.1M | — | — | — |
| Gross profit | $77.1M | $105.1M | $93.1M | $37.9M | $37.5M | $10.8M | $296.3K | -$818.5K |
| Operating income | $42.9M | $63.7M | $51.3M | $19.5M | $20.1M | -$3.3M | -$15.3M | -$16.7M |
| Net income | $26.0M | $38.6M | $108.6M | $19.8M | $20.6M | -$2.8M | -$14.2M | -$14.5M |
| EPS (diluted) | $0.29 | $0.43 | $1.26 | $0.28 | $0.30 | $-0.05 | $-0.25 | $-0.25 |
| EPS (basic) | $0.33 | $0.48 | $1.42 | $0.29 | $0.32 | $-0.05 | $-0.25 | $-0.25 |
| Operating margin | $42 | $50 | — | $49 | $51 | — | — | — |
| Net margin | $25 | $30 | — | $50 | $53 | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $904.1M | $815.6M | $826.1M | $750.9M | $252.6M | $149.6M | $118.8M | $77.6M |
| Total liabilities | $443.2M | $378.6M | $420.8M | $376.7M | $32.0M | $34.7M | $34.2M | $18.9M |
| Stockholders' equity | $460.8M | $437.0M | $405.3M | $374.1M | $220.6M | $114.9M | $84.7M | $58.7M |
| Total current assets | $480.6M | $383.1M | $367.1M | $259.5M | $248.1M | $144.9M | $114.6M | $73.2M |
| Total current liabilities | $187.4M | $128.8M | $174.3M | $133.6M | $31.7M | $34.4M | $33.8M | $18.5M |
| Cash & equivalents | $256.7M | $178.1M | $144.8M | $48.5M | $159.3M | $66.3M | $40.7M | $35.3M |
| Marketable securities (current) | $0 | $0 | $3.7M | $7.2M | $31.4M | $11.2M | $11.0M | $10.7M |
| Accounts receivable | $161.3M | $154.8M | $171.2M | $158.6M | $42.9M | $54.6M | $51.7M | $17.4M |
| Inventory | $38.6M | $30.7M | $29.7M | $28.9M | $9.6M | $7.5M | $7.6M | $6.6M |
| Property, plant & equipment | $7.9M | $6.2M | $6.0M | $4.3M | $1.6M | $1.7M | $1.8M | $1.9M |
| Goodwill | $30.0M | $30.0M | $30.0M | $17.5M | — | — | — | — |
| Intangible assets | $358.5M | $368.8M | $379.1M | $390.0M | $1.7M | $1.8M | $1.8M | $1.9M |
| Accounts payable | $10.2M | $12.8M | $7.9M | $20.5M | $5.8M | $1.9M | $1.7M | $1.3M |
| Accrued liabilities | $173.2M | $112.8M | $163.4M | $109.1M | $25.7M | $32.3M | $32.0M | $17.0M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $2.3M | $2.5M | $2.8M | — | — | — | — | — |
| Common stock & paid-in capital | $78.0K | $78.0K | $79.0K | $78.3K | $74.6K | $67.7K | $64.0K | $57.9K |
| Retained earnings | -$112.0M | -$138.0M | -$176.6M | -$190.6M | -$299.2M | -$319.0M | -$339.6M | -$353.1M |
| Accumulated other comprehensive income (loss) | $2.0K | $2.0K | $3.0K | $87.6K | $79.4K | $84.6K | $91.0K | $89.1K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $86.2M | $42.4M | $94.5M | $30.9M | $30.0M | $19.7M | -$5.6M | -$13.6M |
| Investing cash flow | -$561.0K | $3.0M | $3.3M | -$291.3M | -$20.2M | -$195.0K | -$303.9K | $6.3M |
| Financing cash flow | -$7.1M | -$12.1M | -$1.4M | $150.5M | $83.2M | $6.1M | $11.3M | $14.1M |
| Free cash flow | $85.7M | $41.7M | $92.7M | $30.4M | $30.0M | $19.7M | -$5.6M | -$13.7M |
| Capital expenditures | $561.0K | $729.0K | $1.7M | $505.9K | $24.0K | $10.0K | $10.1K | $9.8K |
| Depreciation & amortization | $10.5M | $10.5M | — | — | $163.0K | $162.0K | — | — |
| Share-based compensation | $4.1M | $4.6M | $10.3M | $4.1M | $2.7M | $3.5M | $3.7M | $1.2M |
| Deferred income taxes | $4.0M | $13.0M | -$25.8M | -$59.7M | $0 | $0 | — | — |
| Change in accounts receivable | $6.4M | -$16.4M | $12.4M | $87.3M | -$11.7M | $3.0M | $34.4M | $17.2M |
| Change in inventory | $7.9M | $1.0M | $800.1K | $642.9K | $2.1M | -$112.0K | $949.9K | $2.6M |
| Change in accounts payable | -$2.8M | $4.9M | -$7.3M | $6.5M | $3.9M | $213.0K | $375.9K | -$2.0M |
| Purchases of investments | — | — | $0 | $5.0M | — | — | — | — |
| Share repurchases | $6.4M | $11.1M | — | — | $0 | $0 | — | — |
| Tax withholding on stock comp | $131.0K | $1.5M | $257.4K | $464.6K | $247.0K | $1.0M | $53.4K | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Gross profit | $275.7M | $40.3M | — | $61.7K | $42.0K |
| Operating income | $150.1M | -$22.4M | -$49.0M | -$30.6M | -$29.4M |
| Net income | $163.1M | -$17.9M | -$46.3M | -$29.7M | -$28.2M |
| EPS (diluted) | $2.04 | $-0.30 | $-0.91 | $-0.74 | $-0.75 |
| EPS (basic) | $2.25 | $-0.30 | $-0.91 | $-0.74 | $-0.75 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $826.1M | $118.8M | $82.1M | $62.0M | $68.9M |
| Total liabilities | $420.8M | $34.2M | $11.9M | $7.0M | $6.1M |
| Stockholders' equity | $405.3M | $84.7M | $70.1M | $55.1M | $62.8M |
| Total current assets | $367.1M | $114.6M | $79.5M | $59.6M | $66.5M |
| Total current liabilities | $174.3M | $33.8M | $11.4M | $6.3M | $5.3M |
| Cash & equivalents | $144.8M | $40.7M | $43.6M | $43.1M | $53.3M |
| Marketable securities (current) | $3.7M | $11.0M | $32.4M | $15.6M | $12.1M |
| Accounts receivable | $171.2M | $51.7M | — | — | — |
| Inventory | $29.7M | $7.6M | $2.1M | — | $3.0K |
| Property, plant & equipment | $6.0M | $1.8M | $1.9M | $1.6M | $1.5M |
| Goodwill | $30.0M | — | — | — | — |
| Intangible assets | $379.1M | $1.8M | — | — | — |
| Accounts payable | $7.9M | $1.7M | $4.3M | $2.2M | $2.2M |
| Accrued liabilities | $161.9M | $32.0M | $7.0M | $4.0M | $3.0M |
| Deferred revenue (current) | — | — | — | — | — |
| Common stock & paid-in capital | $79.0K | $64.0K | $54.9K | $42.8K | $38.1K |
| Retained earnings | -$176.6M | -$339.6M | -$321.7M | -$275.4M | -$245.7M |
| Accumulated other comprehensive income (loss) | $3.0K | $91.0K | $94.1K | $82.7K | $87.1K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $175.0M | -$50.6M | -$38.4M | -$24.4M | -$21.2M |
| Investing cash flow | -$308.4M | $21.2M | -$17.1M | -$3.7M | -$9.1M |
| Financing cash flow | $238.5M | $26.3M | $55.9M | $17.9M | $41.8M |
| Free cash flow | $172.8M | -$50.7M | -$38.7M | -$24.6M | -$22.6M |
| Capital expenditures | $2.3M | $116.0K | $327.3K | $219.4K | $1.4M |
| Share-based compensation | $13.8M | $6.1M | $5.5M | $4.1M | $5.0M |
| Deferred income taxes | -$25.8M | — | — | — | — |
| Change in accounts receivable | $90.9M | $51.8M | — | — | — |
| Change in inventory | $3.5M | $5.5M | $2.1M | -$3.0K | -$145.5K |
| Change in accounts payable | $3.3M | -$2.6M | $2.1M | -$6.6K | — |
| Purchases of investments | $5.0M | — | — | — | — |
| Tax withholding on stock comp | $2.0M | $290.0K | $198.4K | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CRMD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-30 to 2026-09-18
Recent transactions
- Most recent: Dillione Janet (Director) — Option exercise of 48,909 shares on 2026-09-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Dillione Janet | Director | Option exercise | 2026-09-18 | 48,909 |
| Blum Susan | Chief Financial Officer | Tax withholding | 2026-08-29 | 8,424 |
| Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 2026-08-29 | 8,076 |
| Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 2026-08-29 | 8,424 |
| Todisco Joseph | Chief Executive Officer | Grant / award | 2026-02-04 | 77,156 |
| Kaplan Myron | Director | Grant / award | 2026-01-26 | 30,453 |
| Lefkowitz Steven W | Director | Grant / award | 2026-01-26 | 30,453 |
| DUNTON ALAN W | Director | Grant / award | 2026-01-26 | 30,453 |
| Stewart Robert A | Director | Grant / award | 2026-01-26 | 30,453 |
| Duncan Gregory Scott | Director | Grant / award | 2026-01-26 | 30,453 |
| Seckler Michael David | Chief Commercial Officer | Grant / award | 2026-01-08 | 133,156 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-18 | Dillione Janet | Director | Option exercise | 48,909 | — |
| 2026-08-29 | Blum Susan | Chief Financial Officer | Tax withholding | 8,424 | $8.30 |
| 2026-08-29 | Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 8,076 | $8.30 |
| 2026-08-29 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 8,424 | $8.30 |
| 2026-02-04 | Zelnick Kaufman Beth | Chief Legal Officer | Grant / award | 36,006 | $0.00 |
| 2026-02-04 | Hurlburt Elizabeth | Chief Operating Officer | Grant / award | 36,006 | $0.00 |
| 2026-02-04 | Todisco Joseph | Chief Executive Officer | Grant / award | 77,156 | $0.00 |
| 2026-01-26 | Kaplan Myron | Director | Grant / award | 30,453 | $0.00 |
| 2026-01-26 | Dillione Janet | Director | Grant / award | 30,453 | $0.00 |
| 2026-01-26 | Lefkowitz Steven W | Director | Grant / award | 30,453 | $0.00 |
| 2026-01-26 | DUNTON ALAN W | Director | Grant / award | 30,453 | $0.00 |
| 2026-01-26 | Stewart Robert A | Director | Grant / award | 30,453 | $0.00 |
| 2026-01-26 | Duncan Gregory Scott | Director | Grant / award | 30,453 | $0.00 |
| 2026-01-23 | Blum Susan | Chief Financial Officer | Grant / award | 72,820 | $0.00 |
| 2026-01-23 | Blum Susan | Chief Financial Officer | Tax withholding | 9,767 | $7.27 |
| 2026-01-23 | Zelnick Kaufman Beth | Chief Legal Officer | Grant / award | 72,820 | $0.00 |
| 2026-01-23 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 8,803 | $7.27 |
| 2026-01-23 | Hurlburt Elizabeth | Chief Operating Officer | Grant / award | 93,010 | $0.00 |
| 2026-01-23 | Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 10,778 | $7.27 |
| 2026-01-23 | Todisco Joseph | Chief Executive Officer | Grant / award | 225,900 | $0.00 |
| 2026-01-23 | Todisco Joseph | Chief Executive Officer | Tax withholding | 27,306 | $7.27 |
| 2026-01-21 | Dillione Janet | Director | Open market sale | 10,000 | $6.88 |
| 2026-01-17 | Todisco Joseph | Chief Executive Officer | Tax withholding | 22,665 | $6.78 |
| 2026-01-16 | Todisco Joseph | Chief Executive Officer | Option exercise | 29,585 | $3.38 |
| 2026-01-12 | Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 5,794 | $7.15 |
| 2026-01-12 | Todisco Joseph | Chief Executive Officer | Tax withholding | 17,417 | $7.15 |
| 2026-01-12 | Lefkowitz Steven W | Director | Option exercise | 15,000 | $5.63 |
| 2026-01-08 | Seckler Michael David | Chief Commercial Officer | Grant / award | 133,156 | $0.00 |
| 2026-01-02 | Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 10,895 | $12.16 |
| 2026-01-02 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 11,333 | $12.16 |
| 2025-12-30 | DUNTON ALAN W | Director | Option exercise | 20,000 | $4.03 |
| 2025-12-30 | DUNTON ALAN W | Director | Open market sale | 20,000 | $13.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:28 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-19 | 8-K | 2026-10-19 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-29 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-29 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-29 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-07-01 | 8-K | 2026-06-25 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-23 | View on SEC.gov → |
| 2026-06-08 | 8-K | 2026-06-08 | View on SEC.gov → |
Recent news
Headlines about CRMD (CorMedix Inc.). Links open the publisher — we don’t host full articles.
-
CorMedix (NASDAQ:CRMD) Stock Keeps Buy Rating at Needham & Company LLC
MarketBeat · 2026-10-21 -
CRMD Dec 2026 13.000 call (CRMD261218C00013000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-20 -
CRMD Dec 2026 13.000 call (CRMD261218C00013000) interactive stock chart
Yahoo Finance Australia · 2026-10-20 -
CRMD Dec 2026 13.000 call (CRMD261218C00013000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-19 -
CRMD270319P00008000 interactive stock chart | CRMD Mar 2027 8.000 put stock
Yahoo Finance Australia · 2026-10-19 -
Needham Reiterates Buy on Cormedix, Maintains $15 Price Target
Benzinga · 2026-10-19 -
Cormedix gets FDA priority review for Rezzayo label expansion
Seeking Alpha · 2026-10-19 -
Cormedix Rezzayo label expansion under FDA review (CRMD:NASDAQ)
Seeking Alpha · 2026-10-19
No headlines in this category right now — try “All”.